Pnd9 - Migraine Burden Before and After Erenumab Treatment: A Responder Analysis in Difficult-To-Treat Patients

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1976
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prm154 - Modeling Migraine Day Frequency by Responder Status: A Re-Analysis of Data From Erenumab Clinical Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

What Is Treatment Resistance in Psychiatry? A “Difficult to Treat” Concept

World Psychiatry
PsychiatryMental HealthPsychiatric Mental Health
2019English

Erenumab: A Monoclonal Antibody for Migraine Prophylaxis

Prescriber
Pharmacology
2019English

Difficult-To-Treat and Severe Asthma in Adults: Towards a New Treatment Paradigm

Australian journal of general practice
Medicine
2019English

Rare and Difficult to Treat Haematological Diseases

The Lancet Haematology
Hematology
2015English

Is Phrenic Nerve Conduction Affected in Patients With Difficult-To-Treat Asthma?

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
2018English

Fibromyalgia and Myositis Linked to Higher Burden and Disability in Patients With Migraine

SN Comprehensive Clinical Medicine
2019English

074 Early Australian Experience With Erenumab for Chronic Migraine

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

A Case of Difficult-To-Treat Chronic Diverticulitis

Progress of Digestive Endoscopy
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy